Aclaris Therapeutics Inc (FRA:8AT)
€ 0.9182 -0.0174 (-1.86%) Market Cap: 66.10 Mil Enterprise Value: -42.89 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 50/100

Aclaris Therapeutics, Inc. - Special Call Transcript

Jun 26, 2019 / 09:00PM GMT
Release Date Price: €3.79 (-0.97%)
Operator

Good day, ladies and gentlemen, and welcome to the Aclaris presents top line data from AA-201 Topical Phase II trial. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, Ms. Kamil Jackson. You may begin.

Kamil Ali;Jackson
Aclaris Therapeutics, Inc. - Co-Founder, Chief Legal Officer, Chief Compliance Officer & Secretary

Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris.

Please note that earlier today, Aclaris issued its press release announcing results from our AA-201 Topical Phase II clinical trial for our investigational drug ATI-502. For those of you who have not yet seen it, you will find the release posted in the Investors section of our website at www.aclaristx.com.

Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer; and Dr. David Gordon, our Chief Medical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot